^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Elrexfio (elranatamab-bcmm)

    i
    Other names: PF-06863135, PF 06863135, PF06863135, PF‑3135, PF3135, RN 613, RN613, RN-613
    Company:
    Pfizer
    Drug class:
    CD3 agonist, BCMA inhibitor
    Related drugs:
    8d
    Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=64, Not yet recruiting, Case Comprehensive Cancer Center
    New P2 trial
    |
    Elrexfio (elranatamab-bcmm)
    8d
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=59, Active, not recruiting, Pfizer | Trial primary completion date: Apr 2026 --> Jul 2025
    Trial primary completion date
    |
    carfilzomib • dexamethasone • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    15d
    A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" (clinicaltrials.gov)
    P2, N=34, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Jul 2026 --> Mar 2026
    Enrollment open • Trial initiation date
    |
    Elrexfio (elranatamab-bcmm)
    21d
    Delayed response with peripheral blood CD8+ T cell expansion during elranatamab therapy in relapsed/refractory multiple myeloma (PubMed, Rinsho Ketsueki)
    Notably, marked peripheral CD8+ T cell expansion was observed at the onset of response, and counts remained elevated during sustained remission. This case suggests that early sFLC reduction is a useful indicator for treatment continuation, and that peripheral CD8+ T-cell dynamics may serve as an on-treatment response biomarker for elranatamab therapy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Elrexfio (elranatamab-bcmm)
    25d
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=59, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=90 --> 59
    Enrollment closed • Enrollment change
    |
    carfilzomib • dexamethasone • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    1m
    EPIC: Elranatamab in R/R Multiple Myeloma (clinicaltrials.gov)
    P2, N=32, Recruiting, Massachusetts General Hospital | Trial primary completion date: Dec 2025 --> Aug 2026
    Trial primary completion date
    |
    Elrexfio (elranatamab-bcmm) • Abecma (idecabtagene vicleucel)
    1m
    ELISA in Relapsed/Refractory MM (clinicaltrials.gov)
    P2, N=30, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elrexfio (elranatamab-bcmm) • isatuximab subcutaneous (SAR650984 SC)
    2ms
    A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma (clinicaltrials.gov)
    P2, N=26, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    cyclophosphamide • Elrexfio (elranatamab-bcmm)
    2ms
    MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Pfizer | N=34 --> 46
    Enrollment change
    |
    lenalidomide • dexamethasone • Elrexfio (elranatamab-bcmm) • Ogsiveo (nirogacestat)
    2ms
    CA057-1040: Phase 1b/2a Study to Evaluate Mezigdomide in Combination with Elranatamab in Relapsed and/or Refractory Multiple Myeloma (2025-522090-11-00)
    P1/2, N=24, Recruiting, Celgene Corp.
    New P1/2 trial
    |
    dexamethasone • Elrexfio (elranatamab-bcmm) • mezigdomide (CC-92480)
    2ms
    MagnetisMM-9: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (clinicaltrials.gov)
    P2, N=86, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Pfizer
    New trial • Real-world evidence
    |
    Elrexfio (elranatamab-bcmm)